Sheliyan Raveenthiran
Royal Brisbane and Women's Hospital, Redcliffe Hospital, Wollongong Hospital
Papers
3
Total Citations
107
H-Index
3
About
Sheliyan Raveenthiran is a leading researcher in the field of urological oncology, with a primary focus on improving the diagnostic accuracy and surgical management of prostate cancer. His work centers on the comparative evaluation of advanced imaging modalities, specifically multiparametric magnetic resonance imaging (mpMRI) and ⁶⁸Ga-prostate-specific membrane antigen PET/CT (PSMA PET/CT), against gold-standard histopathology from radical prostatectomy specimens. Raveenthiran’s major contribution lies in demonstrating that PSMA PET/CT can identify clinically significant prostate cancers missed by mpMRI, thereby refining preoperative risk stratification and surgical planning. His landmark 2020 study, with 69 citations, showed that PSMA PET/CT outperforms mpMRI in predicting pathological outcomes at radical prostatectomy and pelvic lymph node dissection. In a subsequent large-scale analysis of 1,123 men (33 citations), he confirmed that combining PSMA PET/CT with mpMRI enhances detection of significant disease, challenging the sole reliance on MRI. His work has direct implications for reducing unnecessary biopsies and improving treatment decisions, establishing him as a key voice in the integration of molecular imaging into prostate cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3